Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma

Beatrice Anna Zannetti, Paola Tacchetti, Lucia Pantani, Barbara Gamberi, Patrizia Tosi, Serena Rocchi, Claudia Cellini, Sonia Ronconi, Annalisa Pezzi, Katia Mancuso, Ilaria Rizzello, Isola Caratozzolo, Marina Martello, Luca Dozza, Michele Cavo, Elena Zamagni

Research output: Contribution to journalArticle

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.

Original languageEnglish
Pages (from-to)2071-2078
Number of pages8
JournalAnnals of Hematology
Volume96
Issue number12
DOIs
Publication statusPublished - Dec 2017

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Disease Progression
Standard of Care
Disease-Free Survival
Therapeutics
Multivariate Analysis
Transplants
Recurrence
Drug Therapy
Survival

Keywords

  • Aged
  • Autografts
  • Bortezomib
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Recurrence
  • Secondary Prevention
  • Stem Cell Transplantation
  • Survival Rate
  • Time Factors
  • Clinical Trial
  • Journal Article
  • Multicenter Study

Cite this

Zannetti, B. A., Tacchetti, P., Pantani, L., Gamberi, B., Tosi, P., Rocchi, S., ... Zamagni, E. (2017). Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. Annals of Hematology, 96(12), 2071-2078. https://doi.org/10.1007/s00277-017-3140-5

Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. / Zannetti, Beatrice Anna; Tacchetti, Paola; Pantani, Lucia; Gamberi, Barbara; Tosi, Patrizia; Rocchi, Serena; Cellini, Claudia; Ronconi, Sonia; Pezzi, Annalisa; Mancuso, Katia; Rizzello, Ilaria; Caratozzolo, Isola; Martello, Marina; Dozza, Luca; Cavo, Michele; Zamagni, Elena.

In: Annals of Hematology, Vol. 96, No. 12, 12.2017, p. 2071-2078.

Research output: Contribution to journalArticle

Zannetti, BA, Tacchetti, P, Pantani, L, Gamberi, B, Tosi, P, Rocchi, S, Cellini, C, Ronconi, S, Pezzi, A, Mancuso, K, Rizzello, I, Caratozzolo, I, Martello, M, Dozza, L, Cavo, M & Zamagni, E 2017, 'Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma', Annals of Hematology, vol. 96, no. 12, pp. 2071-2078. https://doi.org/10.1007/s00277-017-3140-5
Zannetti, Beatrice Anna ; Tacchetti, Paola ; Pantani, Lucia ; Gamberi, Barbara ; Tosi, Patrizia ; Rocchi, Serena ; Cellini, Claudia ; Ronconi, Sonia ; Pezzi, Annalisa ; Mancuso, Katia ; Rizzello, Ilaria ; Caratozzolo, Isola ; Martello, Marina ; Dozza, Luca ; Cavo, Michele ; Zamagni, Elena. / Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. In: Annals of Hematology. 2017 ; Vol. 96, No. 12. pp. 2071-2078.
@article{fb8b71e882834da194129ff55d3636aa,
title = "Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma",
abstract = "High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87{\%} of patients. Response to re-induction therapy included complete response (CR) 18{\%}, ≥ very good partial response (VGPR) 48{\%}, and overall response rate (ORR) 83{\%}. Response to sASCT included CR 44{\%}, ≥ VGPR 77{\%}, and ORR 94{\%}. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.",
keywords = "Aged, Autografts, Bortezomib, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Recurrence, Secondary Prevention, Stem Cell Transplantation, Survival Rate, Time Factors, Clinical Trial, Journal Article, Multicenter Study",
author = "Zannetti, {Beatrice Anna} and Paola Tacchetti and Lucia Pantani and Barbara Gamberi and Patrizia Tosi and Serena Rocchi and Claudia Cellini and Sonia Ronconi and Annalisa Pezzi and Katia Mancuso and Ilaria Rizzello and Isola Caratozzolo and Marina Martello and Luca Dozza and Michele Cavo and Elena Zamagni",
year = "2017",
month = "12",
doi = "10.1007/s00277-017-3140-5",
language = "English",
volume = "96",
pages = "2071--2078",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma

AU - Zannetti, Beatrice Anna

AU - Tacchetti, Paola

AU - Pantani, Lucia

AU - Gamberi, Barbara

AU - Tosi, Patrizia

AU - Rocchi, Serena

AU - Cellini, Claudia

AU - Ronconi, Sonia

AU - Pezzi, Annalisa

AU - Mancuso, Katia

AU - Rizzello, Ilaria

AU - Caratozzolo, Isola

AU - Martello, Marina

AU - Dozza, Luca

AU - Cavo, Michele

AU - Zamagni, Elena

PY - 2017/12

Y1 - 2017/12

N2 - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.

AB - High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.

KW - Aged

KW - Autografts

KW - Bortezomib

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Male

KW - Middle Aged

KW - Multiple Myeloma

KW - Recurrence

KW - Secondary Prevention

KW - Stem Cell Transplantation

KW - Survival Rate

KW - Time Factors

KW - Clinical Trial

KW - Journal Article

KW - Multicenter Study

U2 - 10.1007/s00277-017-3140-5

DO - 10.1007/s00277-017-3140-5

M3 - Article

C2 - 29063955

VL - 96

SP - 2071

EP - 2078

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -